康士得说明书
DERSIMELAGON 产品说明书
488 Scientific AbstractsSystemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal modelsPOS0467 DERSIMELAGON, A NOVEL ORAL MELANOCORTIN1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OFSYSTEMIC SCLEROSISM. Kondo1, T. Suzuki1, Y. Kawano1, S. Kojima2, M. Miyashiro1, A. Matsumoto1, G. Kania3, P. Blyszczuk3, R. Ross4, P. Mulipa4, F. Del Galdo4, Y. Zhang5, J. H. W. Distler5. 1Mitsubishi T anabe Pharma Corporation, Research Unit/Immunology & Inflammation, Souyaku Innovative Research Division, Y okohama, Japan;2Mitsubishi T anabe Pharma Corporation, Discovery T echnology Laboratories, Souyaku Innovative Research Division, Y okohama, Japan;3University Hospital Zurich, University of Zurich, Center of Experimental Rheumatology, Department of Rheumatology, Schlieren, Switzerland;4University of Leeds, Leeds Instituteof Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, Leeds, United Kingdom;5Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Department of Internal Medicine 3—Rheumatology and Immunology, Erlangen, GermanyBackground: Activation of melanocortin 1 receptor (MC1R) is known to have broad anti-inflammatory and anti-fibrotic effects. The bleomycin (BLM)-induced skin fibrosis murine model is well-established for systemic sclerosis (SSc). α-mel-anocyte-stimulating hormone, an endogenous ligand of MC1R, inhibits skin fibro-sis and MC1R knock-out enhances skin fibrosis in this model. These pieces of evidence suggest that MC1R agonism has potential in the treatment of SSc. Objectives: Dersimelagon phosphate (MT-7117) is an investigational small molecule that is an orally administered, selective agonist for MC1R. The purpose of this study is to investigate the potential of MT-7117 as a therapeutic agent for SSc by evaluat-ing its efficacy and mechanism of action in complementary preclinical models. The expression and distribution of MC1R in the skin of SSc patients was investigated. Methods: The effects of MT-7117 on skin fibrosis and lung inflammation were eval-uated in BLM-induced SSc murine models that were optimized for prophylactic and therapeutic evaluation. Microarray-based gene expression analysis and serum pro-tein profiling were performed to investigate the mechanism of action of MT-7117 in the BLM-induced SSc models. The effect of MT-7117 on TGF-β-induced activation of human dermal fibroblasts was evaluated in vitro. Immunohistochemical analyses of MC1R expression in skin samples from SSc patients were performed. Results: Prophylactic treatment with MT-7117 (≥0.3 mg/kg/day p.o.) significantly inhibited the increase in collagen content of the skin, the serum level of sur-factant protein D, and the weight of the lungs from BLM-induced skin fibrosis and lung inflammation model. Therapeutic treatment with MT-7117 (≥3 mg/kg/ day p.o.) significantly suppressed skin thickening and the numbers of myofi-broblasts in pre-established BLM-induced skin fibrosis model. Gene array anal-ysis using the BLM-induced SSc model demonstrated changes in numerous categories related to macrophages, monocytes, and neutrophils, followed by endothelial cell-related categories after treatment with MT-7117. In the analy-sis that focused on biological functions, categories of inflammatory response, activation of antigen-presenting cells, angiogenesis, atherosclerosis, vascu-logenesis, and vaso-occlusion were suppressed by MT-7117. In the analysis that focused on molecular signaling pathways, triggering receptor expressed on myeloid cells-1, IL-6, and oncostatin M involved in inflammation, and perox-isome proliferator-activated receptor that is related to fibrosis were all affected by MT-7117. Serum protein profiling using BLM-induced SSc model revealed that multiple SSc-related biomarkers including P-selectin, osteoprotegerin, cys-tatin C, growth and differentiation factor-15 and S100A9 were suppressed by MT-7117. MT-7117 inhibited the activation of human dermal fibroblasts by sup-pressing TGF-β-induced ACTA2 (encoding α-smooth muscle actin) mRNA ele-vation in vitro. Immunohistochemical analyses showed that MC1R positivity was observed in 40 of 50 diffuse cutaneous SSc patients. MC1R was expressed by monocytes/macrophages, neutrophils, blood vessels (endothelial cells), fibro-blasts, and epidermis (keratinocytes) in the skin of SSc patients. Conclusion: MT-7117 demonstrates disease-modifying effects in preclinical mod-els of SSc. Investigations of its mechanism of action and target expression anal-yses indicate that MT-7117 exerts its positive effects by affecting the pathologies of inflammation, vascular dysfunction, and fibrosis through inflammatory cells, endothelial cells, and fibroblasts. In view of its potent beneficial impact on all these three main pathologies of SSc, MT-7117 is a potential therapeutic agent for the treatment of clinically challenging SSc, which has diverse and difficult to treat symp-toms. A phase 2 clinical trial investigating the efficacy and tolerability of MT-7117 in patients with early, progressive diffuse cutaneous SSc is currently in progress. Disclosure of Interests: Masahiro Kondo Employee of: Mitsubishi Tanabe Pharma Corporation, Tsuyoshi Suzuki Employee of: Mitsubishi Tanabe Pharma Corporation, Yuko Kawano Employee of: Mitsubishi Tanabe Pharma Corpora-tion, Shinji Kojima Employee of: Mitsubishi Tanabe Pharma Corporation, Masa-hiko Miyashiro Employee of: Mitsubishi Tanabe Pharma Corporation, Atsuhiro Matsumoto Employee of: Mitsubishi Tanabe Pharma Corporation, Gabriela Kania: None declared, Przemyslaw Blyszczuk: None declared, rebecca ross:None declared, Panji Mulipa: None declared, Francesco Del Galdo Grant/ research support from: Prof. F. Del Galdo received fees and research supportfrom Abbvie, AstraZeneca, Boehringer-Ingelheim, Capella, Chemomab, Kymab, Janssen and Mitsubishi-Tanabe., Yun Zhang: None declared, Jörg H.W. DistlerGrant/research support from: Prof. J.H.W. Distler received consulting fees, lec-ture fees, and/or honoraria from Actelion, Active Biotech, Anamar, ARXX, aTyr,Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, Sanofi-Aventis, RedX, RuiYi and UCB. J. H. W.Distler is stock owner of 4D Science and Scientific head of FibroCure.DOI: 10.1136/annrheumdis-2022-eular.29POS0468 EXTRACELLULAR VESICLES FROM SERUM OFMYOSITIS PATIENTS AS CIRCULATING BIOMARKERSAND DISEASE MEDIATORSS. Kivity1,2, H. Kravitz3, C. Cohen3, D. Margoulis3, M. Amar3, G. Kazimirsky3,D. Ozeri4, A. Dori5, C. Brodie3. 1Meir Medical Center, Rheumatology Unit, KefarSava, Israel;2T el Aviv University, Sackler faculty of Medicine, T el Aviv-Y afo, Israel;3Bar-Ilan University, The Mina and Everard Goodman Faculty of Life Sciences,Ramat Gan, Israel;4T el-HaShomer The Sheba Medical Center, ZabludowiczCenter for Autoimmune Disease, Ramat Gan, Israel;5T el-HaShomer The ShebaMedical Center, Department of Neurology, T alpiot Medical Leadership Program,Sackler Faculty of Medicine, T el Aviv University, Ramat Gan, IsraelBackground: Inflammatory myopathies (IM) are a heterogeneous group of disor-ders characterized by autoimmune inflammatory destruction of skeletal muscles.It is many times associated with lung, skin and joint involvement. Identifying bio-markers that can differentiate IM from other muscle disorders may elucidate the pathophysiology of IM, guide novel therapies, monitor disease activity/responseto treatments and predict prognosis. Exosomes are membrane-bound nanove-sicles with diameters of 30-150 nm that contain multiple proteins, nucleic acid,lipids and other molecules in a tissue- and cell-specific manner. Exosomes are secreted by a large variety of cells, play major roles in cell-cell interactions, andhave recently emerged as circulating biomarkers in a variety of pathological con-ditions, including several autoimmune diseases.Objectives: To characterize exosomes from serum of IM patients, analyze pro-tein expression and study their potential mediators of disease pathologies.Methods: Serum was collected from patients suffering from IM(n=5) and from patients suffering from Becker (BMD) and Duchenne (DMD) muscular dystro-phies (n=6). Exosomes were isolated by Exoquick precipitation and analyzedfor size distribution and by nanoparticle tracking analysis (NTA) and by Westernblot for exosome markers. The effects of the isolated EVs on human satellitecell proliferation and differentiation and macrophage activation were examined. Results: Exosomes from IM patients decreased human satellite cell proliferation (51%, P<0.01) and inhibited their myogenic differentiation as indicated by lower fusionindex (24% inhibition, P<0.01) and expression of myosin heavy chain (72% inhibi-tion, P<0.001). Similar results were obtained also with exosomes derived from DMDand BMD patients; however, their inhibitory effect were more pronounced on MyoG expression. T reatment of macrophages with exosomes from IM patients significantly increased the expression of IL-10 (3-fold, P<0.001), compared to exosomes of healthy controls and DMD patients. Another significant difference was in the expression of sig-naling molecules: Thus, exosomes from BMD patients increased the phosphorylationof Erk and p38, whereas a smaller effect was induced by IM exosomes.Conclusion: Exosomes from IM patients decrease satellite cell proliferationand myogenic differentiation compared to healthy exosomes. In addition, these exosomes increased the expression of IL-10 in macrophages. These effects areunique to exosomes of IM patients compared to muscular dystrophies. These promising results suggest that serum exosomes should be further investigatedas a novel biomarker with potential therapeutic implications.Disclosure of Interests: Shaye Kivity Speakers bureau: BI, Abbvie, Lilly, Pfizer, Janssen, Neopharm, Grant/research support from: Sobi, Haya Kravitz: None declared, Coral Cohen: None declared, Darya Margoulis: None declared, MosheAmar: None declared, Gila Kazimirsky: None declared, David Ozeri Speakers bureau: Neopharm, Consultant of: Abbvie, Amir Dori Grant/research supportfrom: Biogen, Chaya Brodie Grant/research support from: Biogen.DOI: 10.1136/annrheumdis-2022-eular.63POS0469 ENDOTHELIAL TO MESENCHYMAL TRANSITIONAND SENESCENCE ARE PART OF THE FIBROTICPATHOGENESIS IN SYSTEMIC SCLEROSISY. H. Chiu1,2, J. Spierings1, J. M. Van Laar1, J. De Vries-Bouwstra3, M. VanDijk4, R. Goldschmeding4. 1University Medical Center Utrecht, Departmentof Rheumatology and Clinical Immunology, Utrecht, Netherlands;2T ri-ServiceGeneral Hospital, Division of Rheumatology/Immunology/Allergy, T aipei, T aiwan, Republic of China;3Leiden University Medical Center, The Department of on December 24, 2023 by guest. Protected by copyright./ Ann Rheum Dis: first published as 10.1136/annrheumdis-2022-eular.29 on 23 May 2022. Downloaded from。
Air Guard AG-20抗菌氢氧化钙器械具用户手册说明书
USER MANUAL- ENGLISHThank you for choosing Air Guard. Please read the following safety information carefullybefore operating the machine. This information includes important safeguards aboutinstallation, usage, and maintenance. Pay attention to all warning labels and instructionsin this manual and printed on the machine.l Keep this device dry.l Always connect to a grounded circuit to avoid risk of electrocution.l Before connecting the machine to power, always check the voltage indicate on the machine matches to your local AC voltage. Do not use the machine if AC power voltage does not match. l Disconnect the machine from AC power before servicing and when not in use.l If the supply cord is damaged, contact your local dealer for replacement.l This product is for indoor use only! Do not expose to rain or moisture. If fluid is spilled, disconnect AC power and clean with a damp cloth. If fluid is spilled onto electronic parts,immediately unplug the machine and contact your local dealer for advice.l No user serviceable and modifiable parts inside. Never try to repair this product, an unauthorized technician may lead the machine to damage or malfunction.l For adult use only. Children being supervised not to play with the machine. Never leave the machine running unattended.l The machine is not to be used by persons (including children) with reduced physical, sensory or mental capabilities, or lack of experience and knowledge.l Installed in a well ventilated area. Provide at least 50 cm space around the machine.l Never add flammable liquid of any kind to the machine.l Make sure there are no flammable materials close to the machine while operating.l Only use Air Guard Antibacterial Solution. Other solution may lead to heater clog and malfunction.l If the machine fails to work, unplug the machine and stop operation immediately. Contact your local dealer for advice.l Before transporting the machine, make sure the fluid tank is completely drained.l Air Guard Antibacterial Solution may present health risks if swallowed. Do not drink Air Guard solution. Store it securely. In case of eye contact or if solution is swallowed immediately look for medical advice.Immediately upon receiving the antibacterial vaporizer, carefully unpack the carton, check the content to ensure that all parts are present and have been received in good condition. If any parts appear damaged or mishandled from shipping, notify the shipper immediately and retain the packing material for inspection.What is included: 1 x AG-20 Antibacterial Vaporizer1 x Battery1 x Battery Charger1 x Wireless Remote Control1 x FLD Antibacterial Solution1 x User ManualH 238 mmL 293 mmW 108 mmStep3: Connect the battery base or power base to the fog machine. Turn on the machine to start operation.Pull to release locking lever Align and insert head unit to baseBattery and ChargersWhen the LED indicator on the charger turns red, the battery is being charged. When it turns green, the charging process is completed. A low power battery requires approximately 3 hours to be fully charged. A fully charged battery can run the machine for roughly 12 minutes.Plug in the charger Red light indicates charging Green light indicates chargingcompletedOperationManual ModePut DIP switch 1 ~ 9 to OFF position for manual mode.In the manual mode, fog output can be triggered by either keeping holding the handle button or pressing once the button A on the wireless transmitter. To stop fogging, release the handle button or press once the button B on the wireless transmitter.Timer ModeUse the DIP switch located in front of machine to set the timer’s duration (fogging) time. Duration time can be set from 15 to 240 seconds. Put DIP switch to ON position for desired duration time. Longer timer setting overwrites shorter timer setting. For example: When both DIP switch 1 and 9 set to ON position, the duration time will be 240 seconds.Timed fogging can be triggered by either pressing the handle button once or pressing the button A on the wireless transmitter once. When the timed fogging’s time is up, machine stops automatically. To stop timed fogging immediately, press once handle button or press once the button B on the wireless transmmiter.Radio wireless remote control system consists of a transmitter with two buttons to activate and deactivate fogging. The wireless signal receiver (antenna) is attached to the rear panel of AG-20.W-1 Wireless TransmitterPress [A] button to emit fog and press [B] button to stop fogging.Wireless Signal Receiver (Antenna)In an open space, the maximum distance of the radio wireless remote is 50 meters. However, the operating distance depends on obstacle levels.Pairing and Deleting a transmitter with receiverTransmitters can be paired or deleted from the wireless signal receiver. Each receiver can pair up to 5 transmitters. Follow the steps below to pair or delete a transmitter from a receiver.To PairStep 1: Put Dip switch 11 to ON positionStep 2: The red LED indicator on handle starts to blink. Press button A on the transmitter once to pair it with the receiver.Step 3: Once pairing is completed, LED indicator will be constant on for 3 secondsStep 4: Put Dip switch 11 back to OFF position to start operationTo DeleteStep 1: Put the dip switch 10 to ON positionStep 2: The red LED indicator on handle starts to blink. Press button A on the transmitter once to delete it from the receiver.Step 3: The deleting process takes approximately 10 secondsStep 4: Once deleted, the LED indicator will be on for 3 secondsStep 5: Put the dip switch 10 back to the OFF position to start operationTransmitter battery replacementIf the operating distance of the radio wireless remote becomes shorter, it is possible the wireless transmitter’s battery power is getting low and requires a replacement. In order to replace the battery, undo the three screws on the back of transmitter to remove the case. Replace with the same type and specification of battery which is 27A 12V.Use Air Guard FLD / FLV Antibacterial Solution for AG-20. The machine is tested and calibrated with these authorized fluids to achieve the best performance. Warranty will be void, if any other type of liquid is used. Improper use of liquid may lead to machine failure and danger.․It is recommended to run the machine on a monthly basis in order to achieve best performance and output condition.․ Excessive dust, liquid and dirt built up will degrade performance and cause overheating. ․In an event of machine error, contact an authorized distributor/dealer for further technical supports and service.Red LED Indicator on the handleMachine’s Status LED Indicator Ready to fog Constant onProducing fogSlow flash every 0.7 second Low battery Quick flash every 0.3 second Machine errorQucik flash every 0.1 second- Input voltage- Rated power - Warm-up time - Fluid consumption - Fluid tank capacity - Compatible fluid- Ambient temp. range - Control - Dimension - WeightDC 12V (Battery)AC 100-240V, 50-60Hz (Battery charger) 600W1 second (approx.) 14 ml/min0.4 Liter (0.11 Gallon)Air Guard FLD Antibacterial Solution Air Guard FLV Antibacterial Solution 0 °C - 40 °C (32 °F-104 °F)Manual, Timer, Radio Wireless Remote L293 W108 H238 mm (L11.54 W4.25 H9.37 inch) 8.5 kg (18.74 lbs)M22 Moisture Co., Ltd.Tel : +886 3 2227470 Fax : +886 3 2227469 e-mail : ******************.twC08AG0201。
Carter-Hoffmann EVOR208 EVOR240食品保持站说明书
FOOD HOLDING STATIONSMODELS: EVOL208, EVOR208, EVOL240, EVOR240 EVOLTSM208, EVOLTLG208, EVOLTSM240, EVOLTLG240OWNERS / OPERATORS MANUALPart Number: 18400-3178 Printed in The United States of America Rev4: KBA092413TABLE OF CONTENTSPAGE SAFETY PRECAUTIONS 2 FEATURES & SPECIFICATIONS 3 UNPACKING, INSPECTION & FREIGHT DAMAGE 4 INSTALLATION & STARTUP 5 CONTROL PANEL LAYOUT 6 OPERATION 6 CONTROLLER PROGRAMMING INSTRUCTIONS 7 DAILY CLEANING PROCEDURES 8 TIPS FOR CLEANING STAINLESS STEEL 9 WIRING DIAGRAM & REPLACEMENT PARTS LIST 10 TROUBLESHOOTING GUIDE 11-12 WARRANTY STATEMENT 13MANUFACTURED BY:CARTER-HOFFMANN 1551 McCormick Avenue Mundelein, IL 60060 U.S.A.Phone: 847-362-5500 Fax: 847-367-8981 Toll Free: 800-421-3744Email:************************************EVOR208EVOLTLG208 EVOLTSM2083FEATURES & SPECIFICATIONSFeatures & Benefits∙ EVOL208, EVOR208, EVOL240, EVOR240. EVOR models have the small heating cabinet on the right side. EVOL models have the small heating cabinet on the left side.∙ EVOLT models have separate small and large side cabinets.∙ Precision-engineered heat ducts with blower fan for even heat distribution throughout cabinet.∙Each side individually heated with separate, removable heating units. Digitally controlled and monitored tem-perature, with digital temperature read-out; pre-set factory temperatures of 208°F for small warming box and 158°F for large warming box. On/Off toggle switch on each heater. ∙ Designed for over-counter use with angled interior floor.∙ Rod-type wire rack holders (NOT INCLUDED) are removable for cleaning. ∙ Rear and bottom duct assemblies are removable for cleaning.∙ Polycarbonate shields over top of opening with flip up feature on large warming box and sliding doors on small warming box enhance heating operation.∙Supplied with 14/3 HSJO power cord and NEMA L6-15 plug.ModelOverall DimensionsElectrical Information (each heater)Shipping WeightEVOL240 & EVOR240 32.38”H x 19.83”D x 62.25W 240V, 2400W, 10.5A, 50/60Hz, 1Ph 250 lbs EVOL208 & EVOR208 32.38”H x 19.83”D x 62.25W 208V, 2400W, 12A, 50/60Hz, 1Ph 250 lbs EVOLTSM208 32.38 x 19.83 x 17.5 208v, 2400W, 12A, 50/60Hz, 1 Ph 85 EVOLTLG208 32.38 x 19.83 x 46 208v, 2400W, 12A, 50/60Hz, 1 Ph 168 EVOLTSM240 32.38 x 19.83 x 17.5 240V, 2400W, 10.5A, 50/60Hz, 1Ph 85 EVOLTLG24032.38 x 19.83 x 46240V, 2400W, 10.5A, 50/60Hz, 1Ph168EVOR2083194974 Conforms with UL STD 1973194974 Conforms with NSF/ANSI STD 4EVOLTLG208EVOLTSM208Heater serial tag locations Cabinet serial tag (Noteserial number if callingfor service)On/Off Toggle Switches Controllersaux CAUTION:OPERATION Digital DisplayReadoutEVOR208CONTROLLER PROGRAMMING INSTRUCTIONSEach controller has been factory pre-set for an air temperature set point and a low temperature alarm set point. In most cases, these set points will not need to be changed. However, if changes are necessary, the controller is programmable.*Note: If Air Temperature is programmed to another setting, the Low Temperature Alarm Setting will automatical-ly be reset 25 degrees below the Air Temperature setting.To Lock or Unlock the Controller: Press and hold both Arrow Keys at the same time for at least three sec-onds. “oF” will display when the controller is locked; “oN” will display when the controller is unlocked.To View the Temperature Set Point: Press and release the SET buttonTo Change the Temperature Set Point: Turn power ON. Press and hold the SET button for 3 seconds. The current set point will display and “°F” will flash. Push the up or down arrow buttons to raise or lower the tempera-ture set point in 1° increments. Push SET to store the new setting; the new temperate setting will flash 3 times and then the display will revert back to the actual temperature. (If set button is not pushed within 13 seconds, the new setting will be automatically set and the display will revert back to the actual temperature).To Change from °F to °C, contact factory.Factory Preset Set Points Large Side HeaterSmall Side HeaterAir Temperature158°F 208°FLow Temperature Alarm*25°F below set point 25°F below set point Air Temperature Operating Range145° to 185°F165° to 220°FauxAUX Key (inoperable)Set KeyPress and release to display temper-ature set point Up Arrow KeyPress to increase temperature set point (1° increments)Down Arrow KeyPress to decrease temperature set point (1° increments)9TIPS FOR CLEANING STAINLESS STEELCAUTION:Cleansers, detergents, degreasers, sanitizers, or bleaching agents that contain chlorides or phosphates will cause permanent damage to stainless steel products. The damage appears as pits, eruptions, voids, small holes, severe discoloration or dulling of the metal finish.Water with high chloride content can also damage stainless steel. If unsure of your water quality, we recom-mend you have it tested. THIS DAMAGE IS PERMANENT, COSTLY TO REPAIR, AND IS NOT COV-ERED BY THE WARRANTY .RECOMMENDED TIPS FOR CLEANING STAINLESS STEELPurpose Frequency Cleaning Agent Method of Application Routine Daily Soap, ammonia Sponge with cloth, rinse with clear water cleaning detergent and water and wipe dry.Smears/ As Stainless steel cleaner Rub with soft cloth as directed on package. Fingerprints needed or similar products Rub in direction of grain of stainless steel. Do not use on vinyl trim.Stubborn Daily Any chloride-free Apply with damp sponge or cloth. Rub in spots and as or direction of grain of stainless steel. Rinse stains needed phosphate-free thoroughly, especially if cleaner contains cleaner chlorine bleach, do not use on vinyl trim. Hard water Daily Vinegar Swab with cloth. spots as needed Rinse with water and wipe dry.10WIRING DIAGRAMREPLACEMENT PARTS LISTCabinet serial tag。
戈舍瑞林植入剂说明书
核准日期：2011年12月31日修订日期：2012年04月01日2012年08月20日2013年02月19日2013年07月18日2016年11月01日2016年11月07日戈舍瑞林植入剂说明书请仔细阅读说明书并在医生指导下使用【药品名称】通用名称：戈舍瑞林植入剂【成份】活性成份为：戈舍瑞林活性成份的结构式为：分子式：C59H84N18O14 C2H4O2分子量:1329辅料：丙交酯/乙交酯聚合物、醋酸【性状】本品为白色至乳白色圆柱状聚合物，无可见异物或几乎无可见异物，聚合物预填充在特殊注射装置中。
【适应症】本品适用于可用激素治疗的前列腺癌。
该适应症主要基于以下临床试验结果：1．用于治疗转移性前列腺癌。
与手术去势相比，使用本品治疗可获得相似的生存获益。
(见【临床试验】研究1、2)2．作为手术去势治疗的替代选择，用于治疗局部晚期前列腺癌。
与抗雄激素治疗相比，使用本品治疗可获得相似的生存获益。
(见【临床试验】研究3) 3．在高危局限性或局部晚期前列腺癌患者中，作为放疗的辅助治疗方案。
研究表明，患者使用本品治疗之后，无疾病生存期和总生存期得到改善。
(见【临床试验】研究4、5)4．在高危局限性或局部晚期前列腺癌患者中，作为放疗之前的新辅助治疗方案；研究表明，患者使用本品治疗之后，无疾病生存期得到改善。
(见【临床试验】研究6)5．在具有疾病进展高度风险的局部晚期前列腺癌患者中，作为根治性前列腺切除术的辅助治疗方案；研究表明，患者使用本品治疗之后，无疾病生存期得到改善。
(见【临床试验】研究7、8)建议主治医生根据患者自身状况综合考虑治疗选择。
【规格】10.8 mg/支(以戈舍瑞林计)。
【用法用量】使用剂量成年男性(包括老年人)：在腹前壁皮下注射本品10.8 mg一支，每12周一次。
对于本品的使用疗程尚无统一标准，临床治疗时应根据患者的具体情况制定相应的治疗方案及疗程。
在临床试验中本品用法具体如下：1.作为转移性前列腺癌的内分泌治疗，在本品对比手术去势的两项随机对照研究中本品为长期使用(详见【临床试验】研究1、2)；2.作为局部晚期前列腺癌的内分泌治疗，在本品对比康士得150mg的两项随机对照研究中本品为长期使用，详见【临床试验】研究3；3.作为高危局限性或局部晚期前列腺癌放疗的辅助治疗，EORTC22863研究中本品从放疗开始的第一天使用，持续使用3年；RTOG85-31研究中本品从放疗的最后一周开始使用，持续使用或至疾病进展，详见【临床试验】研究4、5；4.作为高危局限性或局部晚期前列腺癌放疗前的新辅助治疗，RTOG8610研究中本品从放疗前的2个月开始使用，放疗期间继续使用，详见【临床试验】研究6；5.作为具有疾病进展高度风险的局部晚期前列腺癌根治性手术的辅助治疗，ECOG7887研究中本品持续使用；另一项研究中本品在根治性手术后15天之内使用，并持续使用；详见【临床试验】研究7、8。
Orthomol 产品说明书
Orthomol pharmazeutische Vertriebs GmbH in Langenfeld, Germany, is leading the way in the field of orthomolecular nutritional medicine. For more than 25 years, the company has been developing and marketing an extensive range of food supplements such as balanced dosage and diagnosis-based micronutrient compositions which are available from dispensing chemists. Product development and production are governed by the comprehensive, international food safety and quality standard ISO 22000 which ensures highest quality and safety – from development and raw material selection, right up to the finished product. Over 400 employees work for Orthomol at its three sites in Langenfeld and in field services. Annually over 50 million pouches and 12 million drink bottles leave the premises. For more P h a r m a S o l u t i o nOrthomol's sites in Langenfeld are home not just to the company's R&D, medicine and marketing departments, but also to quality assurance, which is a key focus within the company. From the moment of commissioning, the new two-lane checkweigher has provided stable, reliable weighing results, checking the filling process of "Orthomol Immun" – a dietary food product with immune-relevant micronutrients in portion sachets. Any sachet not correctly filled is reliably excluded from the packaging process by the checkweigher using fast-action lift gate conveyors.Strict quality standards metThe company's balanced dosageproducts include vitamins,minerals, trace elements andsecondary plant compounds which are produced in seven formats,including granules for makingdrinks, tablets, capsules and asThe lift gate conveyors of this C35 AdvancedLine open up against the transport direction to reject products; this is a very space saving and gentle solution which, in many cases, is more suitable for a dual lane or multi-lane checkweigher than air blasts (air jets) or pneumaticpushers. The sachet in this photo is a test sample.2P h a r m a S o l u t i o nC-Series checkweighers provide single-lane or cumulated values at the touch of a keyThe dual lane checkweighing system in the Orthomol Immun line checks up to 120 sachets per minute for correct weight. A clear weighing terminal provides insight into production, giving a quick overview of the results from both lanes. Information from one of the two lanes can be selected at the touch of a key, and the lane concerned can be identified at a glance. Data can also be displayed separately for each lane or as a total.Changeover to another product in no time at allFurthermore, the large memory of product setups facilitates easy changeovers as Mr. Blatancic testifies, "Every two days there's a product changeover in this production line and the C35AdvancedLine can be changed to another product in no time at all."ready-made drinks. It goes without saying that tight tolerances have to be applied to the production of such high-value products, which makes highly-accurate dynamic weighing technology mandatory. "A trusting relationship with our suppliers is important to us," explains Alen Blatancic, head of technical teams. "We've found a partner in METTLER TOLEDO who meets our strict quality standards and has successfully accompanied us for very many years."The new C35 AdvancedLineexcels in high weighing accuracy and throughput, and its versatile product handling features can be flexibly adapted to changing requirements in Orthomol's production lines. Capable of achieving an accuracy of up to 0.1 g, the checkweigher's weighingrange covers products from 3 g to 10 kg, making it suitable for use in many different production lines or line sections of the factory.Access to "moving parts" areas – such as the belt conveyors and lift gate conveyors – is shielded by safeguards. Changeover to another product is just as easy as calling up statisticalinformation from one of the two checkweighing lanes.C35 Pharma checkweigher, a variant of C35 AdvancedLine3To allow for asynchronous and independent operation of the two lanes, each lane can be individually controlled if need be. Moreover, if one lane breaks down, the second weighing lane will continue to work undisturbed.The METTLER TOLEDO service network of technical experts ensures that any repair Orthomol requests will be carried out quickly and meticulously so that production keeps running smoothly. "Besides a reliable product, a fast and trustworthy installation and repair service is essential for us," adds Mr. Blatancic.METTLER TOLEDO is a leading global supplier of checkweighers, metal detectors, x-ray inspection and vision inspection systems. More information:/piA multi-lane checkweigher (example with ten lanes)METTLER-TOLEDO Group Product Inspection Division Email:*************************Web site: /piSubject to technical changes.© 10/2017 Mettler-Toledo Garvens GmbH PI-CW-CS-DE-Orthomol2017-10 2017Guidelines for weighing technology – Creating an effective checkweighing program The "Principles of Checkweighing" guide is recommended as a reference document. It offers insights into all aspects of checkweighing, starting with the basic principles up to the implementation of a comprehensive checking program.This 70-page FREE guide helps producers as a companion document for setting up this sort of weighing program, and is required reading for everyone who has anything to do with checkweighing systems./cwguideCheckweighing About Mettler-Toledo Product Inspection:Vision Inspection X-ray InspectionMetal Detection Track & TraceThe Product Inspection Division of METTLER TOLEDO is a leader in the field of automated inspection technology. Our solutions increase process efficiency for manufacturers while supporting compliance with industry standards and regulations. Our systems also deliver improved product quality which helps to protect the welfare of consumers and reputation of manufacturers.。
比卡鲁胺片(康士得)
请仔细阅读说明书并在医师指导下使用。
【药品名称】通用名称：比卡鲁胺片商品名称：康士得/CASODEX英文名称：Bicalutamide Tablets汉语拼音：Bikalu’an Pian【成分】本品主要成分为比卡鲁胺化学名称：（±）-N-［4-氰基-3-（三氟甲基）苯基］-3-［（4-氟苯基）磺酰基］-2-羟基-2-甲基丙胺酰化学结构式：分子式：C18H14N2O4F4S分子量：430.37【性状】本品为白色薄膜衣片，除去包衣后显白色。
【适应症】1）50mg每日：与促黄体生成素释放激素（LHRH）类似物或外科睾丸切除术联合应用于晚期前列腺癌的治疗。
2）150mg每日：用于治疗局部晚期、无远处转移的前列腺癌患者，这些患者不适宜或不愿接受外科去势术或其他内科治疗。
【规格】（1）50mg （2）150mg【用法用量】50mg片剂与促黄体生成素释放激素（LHRH）类似物或外科睾丸切除术联合应用于晚期前列腺癌的治疗。
成人成年男性包括老年人：一片（50mg），一天一次，用本品治疗应与LHRH类似物或外科睾丸切除术治疗同时开始。
儿童本品禁用于儿童。
肾损害对于肾损害的病人无需调整剂量。
肝损害对于轻度肝损害的病人无需调整剂量，中重度肝损伤的病人可能发生药物蓄积（见注意事项）150mg 片剂用于治疗局部晚期、无远处转移的前列腺癌患者，这些患者不适宜或不愿接受外科去势术或其他内科治疗。
成年男性包括老年人：口服，一天一次，一次一片（150mg）。
本品应持续服用至少两年或到疾病进展为止。
肾损害：对于肾损害的病人无需调整剂量。
肝损害：对于轻度肝损害的病人无需调整剂量，中重度肝损伤的病人可能发生药物蓄积（见“注意事项”）【不良反应】1）50mg每日，用于与促黄体生成素释放激素（LHRH）类似物或外壳睾丸切除术联合应用于晚期前列腺癌的治疗：本品一般来说有良好的耐受性，少有不良反应而停药的情况。
表一不良反应发生频率1.可随睾丸切除术减轻。
Halogen Moisture Analyzer操作指南说明书
R e f e r e n c e P a p e rpage two.2R e f e r e n c e P a p e rMethod Development in Three StepsIf you know the moisture content of your sample (previously determined using the drying oven), you can use our simple three-step process to quickly setup a drying method on your halogen moisture analyzer producing the same results in minutes instead of hours. In case you do not know the moisture content of your sample or you do not have a drying oven method, the Moisture Analysis Experts from METTLER TOLEDO can also give guidance to support you.Methods for Samples in the Food and Chemical IndustryA selection of proven methods are summarized in the table below. You can use the described moisture analyzer methods directly or adjust the method parameters according to your requirements. Please pay attention to the information provided on sample preparation.Sample Drying Temper-ature [°C]DryingProgramSampleWeightSwitch-offcriterionResult[% MC]Measurementtime [min]SamplepreparationTomato Juice 130Rapid 3 g Auto95.278Mix sample, apply evenly toglass fiber filter with pipetteHazelnuts (ground)130Standard 4 g Auto 4.535Mix sample, use spatula to dis-tribute evenly on the sample panButter110Standard 3 g Auto14.818Allow sample to warm to roomtemperature, spread evenly onthe sample pan.Yogurt (plain)105Rapid 3 g Auto85.2613Mix sample, apply evenlyto glass fiber filter.Shampoo160Rapid 3 g Auto85.129Mix sample, apply evenly toglass fiber filter with pipette.Washing up liquid 150Rapid 3 g Auto80.027Mix sample, apply evenly toglass fiber filter with pipette.Liquid Soap 150Rapid 3 g Auto85.2311Mix sample, apply evenly toglass fiber filter with pipette.METTLER TOLEDO recommends that you conduct a comparative test to verify that the results correspond to the reference procedure (typically the drying oven). The data provides a concrete reference point for setting the drying parameters in order to quickly obtain similar results from the measurements taken in the drying oven. Please contact our Moisture Analysis Experts for any further assistence.Visit our website to access drying methods for many more samples:/moisture-methodsFor further tips read the “Guide to Moisture Analysis”:/moisture-guideComplete the elearning to learn about best practice in halogen moisture analysis:/moisture-elearningMettler-Toledo GmbHCH-8606 Greifensee, Switzerland Tel. +41-44-944 22 11 Subject to technical changes© 11/2016 Mettler-Toledo GmbH 30382491Global MarCom 2085 JS /moistureFor more information。
比卡鲁胺片的研制
广
州
化
工
Ｖｏ １ ． ４１ Ｎｏ． ２ ３ Ｄｅ ｃ ｅ ｍｂｅ ｒ ． ２ ０１ ３
Ｇ ｕ ａ ｎ ｇ ｚ ｈ ｏ ｕ Ｃ ｈ ｅ ｍｉ ｃ ａ ｌ Ｉ ｎ ｄ ｕ ｓ ｔ ｒ ｙ
比 卡 鲁 胺 片 的 研 制
于淑香 ，欧仁珊
比卡 鲁 胺 片 属 于抗 肿 瘤 药 物 ，它 与 促 黄 体 生 成 素 释 放 激 素
１ ． １ 辅 料种 类及 用量选 择
（ Ｌ ＨＲ Ｈ） 类似物 或外 科睾 丸切除术联 合应 用于 治疗晚期 前列腺 根据 Ｆ Ｄ Ａ官方 网站 Ｃ Ａ Ｓ Ｏ Ｄ Ｅ Ｘ （ 康 士得 ） 使 用说 明书 ，比卡 癌 ，属于非 甾体类抗雄激 素药物 ，没有 其他 内分泌作 用 ，它 与 鲁胺 片素片的非活性成分包括乳 糖 、硬脂 酸镁 、聚维 酮 、羧 甲 雄激素受体 结 合而 不 激活 基 因表 达 ，从 而 抑制 了雄 激 素 的刺 基淀 粉钠 ；薄膜衣包含羟丙 甲纤维素 、聚 乙二醇 、二氧化钛 。 激 ，导致前列腺肿瘤 的萎缩 。 将 比卡鲁胺 和乳糖 、硬脂 酸镁 、聚维 酮 、羧 甲基 淀粉 钠 、 比卡鲁胺片 由英 国 阿斯利 康 （ Ａ ｓ ｔ ｒ ａ Ｚ ｅ ｎ ｅ ｃ ａ ） 制 药公 司开 发 ， 欧巴代进行原 辅料 相容性研究 ， 结果 表 明以上各个 辅料 和原料 于２ ０ ０ ８年 １ ２月 １ ９日以商品名康士得在美 国获准上市 。 的相 容 性 良好 。 薄膜包衣机 （ Ｂ Ｙ一 ２ ０ ０ ） ，吉首 市 中诚 制药 机械厂 ；电子天 参考康士得 的辅料 种类 ，并结合 原辅料 相容性 的试验 结果 平（ Ｂ Ｓ Ａ ２ ２ ３ Ｓ ） ，赛多利斯科学仪器 （ 北京 ） 有 限公司 ；电热 鼓风 及参考 文 献 ，选 择 乳 糖 、交 联 羧 甲 基 纤 维 素 钠 、聚 维 酮 干燥箱 （ Ｇ Ｚ Ｘ一 ９ ４ ２ ０ ＭＢ Ｅ ） ，上海博 迅实业 有限公 司 ；单 冲压片 Ｋ ９ ０ 、硬脂酸镁作为 自制 比卡鲁胺 片的辅 料。包衣 材料 选 择 的 机（ Ｃ ＆ Ｃ ６ Ｏ Ｏ Ｂ ） 北京 创 博佳 维科 技 有 限公 司 ；卤素 水份 测 定仪 是欧 巴代 。 （ ＭＢ ３ ５ ） 奥豪 斯 国际 贸易 （ 上海） 有 限 公 司 ；智 能 片 剂 硬度 仪
诺达明复方磺胺甲恶唑分散片药品说明书
诺达明复方磺胺甲噁唑分散片药品名称：通用名称：复方磺胺甲噁唑分散片英文名称：COMPOUND SULFAMETHOXAZOLE DISPERSIBLE TABLETS成份：本品为复方制剂，每片含活性成分磺胺甲恶唑0.4G和甲氧苄啶0.08G。
适应症：近年来由于许多临床常见病原菌对本品往往呈现耐药，故治疗细菌感染时需参考药敏结果，本品的主要适应症为敏感菌株所致的下列感染：1.大肠埃希菌、克雷伯菌属、肠杆菌属、奇异变形杆菌、普通变形杆菌和莫根菌属敏感菌株所致的尿路感染。
2.肺炎链球菌或流感嗜血杆菌所致2岁以上小儿的急性中耳炎。
3.肺炎链球菌或流感嗜血杆菌所致的成人慢性支气管炎急性发作。
4.由福氏或宋氏志贺菌敏感菌株所致的肠道感染、志贺菌感染。
5.治疗卡氏肺孢子虫肺炎，本品系首选。
6.卡氏肺孢子虫肺炎的预防，可用已有卡氏肺孢子虫病至少一次发作史的患者，或H用法用量：1成人常用量治疗细菌性感染，一次甲氧苄啶160MG和磺胺甲唑800MG，每12小时服用1次。
治疗卡氏肺孢子虫肺炎，一次甲氧苄啶3.75～5MG/KG和磺胺甲唑18.75～25MG/KG，每6小时服用1次。
成人预防用药：初予甲氧苄啶160MG和磺胺甲唑800MG，一日2次，继以相同剂量一日服1次，或一周服3次。
2小儿常用量2个月以下婴儿禁用。
治疗细菌感染，2个月以上体重40KG以下的婴幼儿按体重口服一次SMZ20～30MG/KG及TMP4～6MG/KG，每12小时1次；体重40KG的小儿剂量同成。
不良反应：1.过敏反应较为常见,可表现为药疹,严重者可发生渗出性多形红斑、剥脱性皮炎和大疱表皮松解萎缩性皮炎等；也有表现为光敏反应、药物热、关节及肌肉疼痛、发热等血清病样反应。
偶见过敏性休克。
2.中性粒细胞减少或缺乏症、血小板减少症及再生障碍性贫血。
患者可表现为咽痛、发热、苍白和出血倾向。
3.溶血性贫血及血红蛋白尿。
这在缺乏葡萄糖-6-磷酸脱氢酶的患者应用磺胺药后易于发生,在新生儿和小儿中较成人为多见。
德国常用药品说明书(仅供参考)
德国电解质水适合人群：三个月以上婴幼儿使用方法：一袋配200ml水，即冲即喝，冲配后的电解质水在1小时内喝完。
否则放入冰箱，冰箱里最长存放24小时。
电解质粉请干燥避光保存，存放温度不能超过25摄氏度，放在儿童不能够到的地方。
产品描述：每一小包含钠0.47克，氯化钾0.3克，葡萄糖一水合物3.56克，二钠柠檬酸1.5H20 0.53克。
当宝宝腹泻，发烧，流汗，疲劳，沐浴后，外出游玩等时，为宝宝补充体液，恢复肌体平衡。
婴儿在运动或沐浴后身体水分流失较多，或者在发烧与腹泻时，尤其需要补充水分,保持电解质平衡，恢复体能。
与婴儿体质相同的渗透压，帮助宝宝更好的吸收水分！不含人工甘味剂、香料、色素及防腐剂。
注意事项：肾病患者慎用出现恶心、呕吐停用开包后1小时内冲饮，开封后可放冰箱里保存24小时，超过24小时请丢弃已冲过的不能二次加热（包括温奶器）如脱水症状无改善或加重，请速送医求治产品名称】德国Octenisept伤口消毒促愈合喷雾【产品规格】50 ml/支【适用人群】一周岁以上儿童及成人【产品功效】伤口消毒、促使伤口愈合【使用方法】对着皮肤的小伤口轻轻一喷，即可！【简介】这款购于德国药店的伤口消毒促愈合喷雾，为广谱、高效杀菌消毒液，它可以为您提供360度防护。
为皮肤的小伤口、小炎症等进行消毒。
在烫伤、烧伤、冻伤、割伤时可临时做伤口的紧急处理！在进行消毒的过程中，同时促进伤口的愈合，无痛配方，让宝宝和您远离疼痛并尽速恢复！医用级产品，零距离亲和肌肤，更贴近高品质生活黏膜应用无刺激【产品名称】德国原装Hexal Paracetamol 125mg婴儿止痛退烧栓【德语名称】Paracetamol 125ml Hexal Zaepfchen【产品规格】10 粒装，PZN：7524663（注：产品的包装可能改变，但是PZN不会变）【主要成分】125mg对乙酰氨基酚（英文：Paracetamol或Acetaminophen，又称醋氨酚）。
康士得说明书
康士得说明书【药品名称】商品名：康士得通用名：比卡鲁胺片【成分】比卡鲁胺 bicalutamide【药物分类】抗肿瘤药【性状】本药为白色薄膜衣片。
【药理作用】本药属于非甾体类抗雄激素药物，没有其它激素的作用，它与雄激素受体结合而使其无有效的基因表达，从而抑制了雄激素的刺激，导致前列腺肿瘤的萎缩。
本药是消旋物，其抗雄激素作用仅仅出现在(R)-结构对应体上。
【药代动力学】本药经口服吸收良好。
没有证据表明食物对其生物利用度存在任何临床相关的影响。
(S)-异构体相对(R)-异构体消除较为迅速，后者的血浆半衰期为1周。
在本药的每日用量下，(R)-异构体因其半衰期长，在血浆中蓄积了约10倍，因此非常适合每日1次的日服。
本药与血浆蛋白高度结合(96%)，并被广泛代谢(经氧化及葡萄糖醛酸化)，其代谢产物以几乎相同的比例经肾及胆消除。
【适应症】与黄体生成素释放激素类似物或外科睾丸切除术联合应用于晚期前列腺癌的治疗。
【用法用量】成人男性50 mg，每日1次，应与黄体生成素释放激素类似物或外科睾丸切除术同时开始。
【不良反应】面色潮红，瘙痒，乳房触痛和男性乳房女性化，腹泻、恶心、呕吐，乏力。
暂时性肝功改变（转氨酶升高，黄疸）。
本药与LHRH类似物联用，进行临床研究期间还观察到下列副作用(可能与药物相关且发生率大于1%)，这些副作用与药物的使用没有因果关系，有些是老年人日常固有的。
心血管系统：心力衰竭。
消化系统：厌食、口干、消化不良、便秘、腹痛、胃肠胀气。
中枢神经系统：头晕、失眠、嗜睡、性欲减低。
呼吸系统：呼吸困难。
泌尿生殖系统：阳痿、夜尿增多。
血液系统：贫血。
皮肤：脱发、皮疹、出汗、多毛。
代谢及营养：糖尿病、高血糖、周围性水肿、体重增加或减轻。
其他：胸痛、头痛、骨盆痛、寒战。
【禁忌症】对本药过敏者，以及妇女、儿童。
【注意事项】中、重度肝损伤病人可能发生药物蓄积，因此应慎用。
【药物相互作用】本药与黄体生成素释放激素（LHRH）类似物之间无任何药效学或药代动力学方面的相互作用。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
康士得说明书
【药品名称】商品名：康士得通用名：比卡鲁胺片
【成分】比卡鲁胺 bicalutamide
【药物分类】抗肿瘤药
【性状】本药为白色薄膜衣片。
【药理作用】
本药属于非甾体类抗雄激素药物，没有其它激素的作用，它与雄激素受体结合而使其无有效的基因表达，从而抑制了雄激素的刺激，导致前列腺肿瘤的萎缩。
本药是消旋物，其抗雄激素作用仅仅出现在(R)-结构对应体上。
【药代动力学】
本药经口服吸收良好。
没有证据表明食物对其生物利用度存在任何临床相关的影响。
(S)-异构体相对(R)-异构体消除较为迅速，后者的血浆半衰期为1周。
在本药的每日用量下，(R)-异构体因其半衰期长，在血浆中蓄积了约10倍，因此非常适合每日1次的日服。
本药与血浆蛋白高度结合(96%)，并被广泛代谢(经氧化及葡萄糖醛酸化)，其代谢产物以几乎相同的比例经肾及胆消除。
【适应症】与黄体生成素释放激素类似物或外科睾丸切除术联合应用于晚期前列腺癌的治疗。
【用法用量】成人男性50 mg，每日1次，应与黄体生成素释放激素类似物或外科睾丸切除术同时开始。
【不良反应】
面色潮红，瘙痒，乳房触痛和男性乳房女性化，腹泻、恶心、呕吐，乏力。
暂时性肝功改变（转氨酶升高，黄疸）。
本药与LHRH类似物联用，进行临床研究期间还观察到下列副作用(可能与药物相关且发生率大于1%)，这些副作用与药物的使用没有因果关系，有些是老年人日常固有的。
心血管系统：心力衰竭。
消化系统：厌食、口干、消化不良、便秘、腹痛、胃肠胀气。
中枢神经系统：头晕、失眠、嗜睡、性欲减低。
呼吸系统：呼吸困难。
泌尿生殖系统：阳痿、夜尿增多。
血液系统：贫血。
皮肤：脱发、皮疹、出汗、多毛。
代谢及营养：糖尿病、高血糖、周围性水肿、体重增加或减轻。
其他：胸痛、头痛、骨盆痛、寒战。
【禁忌症】对本药过敏者，以及妇女、儿童。
【注意事项】中、重度肝损伤病人可能发生药物蓄积，因此应慎用。
【药物相互作用】
本药与黄体生成素释放激素（LHRH）类似物之间无任何药效学或药代动力学方面的相互作用。
与常见的处方药合用未出现相互作用。
在每天剂量高达150 mg 时未发现酶诱导作用。
体外研究表明，本药可以与双香豆素类抗凝剂，如华法令竞争其血浆蛋白结合点，因此建议在已经接受双香豆素类抗凝剂治疗的病人，如果开始服用本药，应密切监测凝血酶原时间。
【药物过量】
没有人类过量的经验，没有特效的解药，应该对症治疗。
透析可能无效，因
为本药与血浆蛋白高度结合，且在尿液中以非原形排泄。
但一般的支持疗法是需要的，这包括生命体征的密切监测。
【制造商】阿斯利康
【参考价】1450元
【规格】50mg*28片
【贮藏/有效期】小心贮存30°C以下。